This week in Drug Discovery (3 – 7 November)
News round-up for 3 – 7 November by Bruno Quinney, Content Team at DDW.
This week’s leading story is a positive development in biopharma, with top companies reporting market growth in Q3 of 2025. Elsewhere, new research could help combat yellow fever and weight loss, while £500,000 was awarded to a biotech company to develop a DMD therapy.
The top stories:
Top biopharma companies report 4% market growth in Q3 2025
The top 20 global biopharmaceutical companies experienced mixed individual market capitalisation performances in Q3 2025, with those experiencing robust pipeline progress reaping success.
New research paves way for yellow fever vaccine development
Researchers have captured the first-ever high-resolution images of yellow fever virus (YFV), which could pave the way for vaccine design.
FDA approval of first TK2d offers ‘hope for the future’
The US Food and Drug Administration (FDA) has approved the first treatment for thymidine kinase 2 deficiency (TK2d), paving the way for landmark treatment options for the mitochondrial disease.
Twice-yearly antibody shows strong therapeutic potential for weight-loss
iBio has announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data.
Duchenne UK hands out £500,000 award to develop DMD therapy
Duchenne UK has awarded £500,000 ($653,000) to biotech company MyoGene Bio to support the development of an innovative gene editing therapy for Duchenne muscular dystrophy (DMD).
Read more…
